Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 625 of 866 entries
View as:

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.

Phase: N/A Priority: Normal
NCT ID: NCT06414798 Org: User:
Start: 05/13/24 End: 02/08/25 Due: 02/08/26

A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

Phase: N/A Priority: Normal
NCT ID: NCT04169373 Org: User:
Start: 11/26/19 End: 02/21/25 Due: 02/21/26

Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01794520 Org: User:
Start: 10/10/12 End: 11/29/21 Due: 11/29/22

A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation

Phase: N/A Priority: Normal
NCT ID: NCT03873857 Org: User:
Start: 02/25/19 End: 09/12/22 Due: 09/12/23

A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

Phase: N/A Priority: Normal
NCT ID: NCT01931670 Org: User:
Start: 09/09/13 End: 12/19/16 Due: 12/19/17

A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT06054425 Org: User:
Start: 11/20/23 End: 05/06/24 Due: 05/06/25

A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)

Phase: N/A Priority: Normal
NCT ID: NCT02955212 Org: User:
Start: 01/03/18 End: 09/03/20 Due: 09/03/21

A Study to Assess Persistence, Adherence and Changes in Disease Activity in the Children Population of Juvenile Arthritis Patients Treated With Adalimumab (HUMIRA®)

Phase: N/A Priority: Normal
NCT ID: NCT03383263 Org: User:
Start: 05/04/18 End: 09/14/20 Due: 09/14/21

A Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST)

Phase: N/A Priority: Normal
NCT ID: NCT03505892 Org: User:
Start: 06/05/18 End: 10/25/21 Due: 10/25/22

An Observational Study to Assess the Impact of Upadacitinib in Adult Hungarian Participants With Moderate to Severe Rheumatoid Arthritis (RA) in Real-World Practice

Phase: N/A Priority: Normal
NCT ID: NCT05327920 Org: User:
Start: 04/20/22 End: 04/22/24 Due: 04/22/25

Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.

Phase: N/A Priority: Normal
NCT ID: NCT05930275 Org: User:
Start: 02/19/24 End: 09/30/28 Due: 09/30/29

A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)

Phase: N/A Priority: Normal
NCT ID: NCT03859869 Org: User:
Start: 02/25/20 End: 03/23/22 Due: 03/23/23

A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence

Phase: N/A Priority: Normal
NCT ID: NCT06387394 Org: User:
Start: 04/22/24 End: 12/31/25 Due: 12/31/26

A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06406348 Org: User:
Start: 05/09/24 End: 04/30/25 Due: 04/30/26

Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT02906488 Org: User:
Start: 09/12/16 End: 08/29/25 Due: 08/29/26

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

Phase: N/A Priority: Normal
NCT ID: NCT03213457 Org: User:
Start: 07/07/17 End: 12/06/23 Due: 12/06/24

A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female Participants

Phase: N/A Priority: Normal
NCT ID: NCT06742086 Org: User:
Start: 12/19/24 End: 09/30/25 Due: 09/30/26

A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01794507 Org: User:
Start: 11/19/12 End: 07/16/19 Due: 07/16/20

An Observational Study to Evaluate Impact of CRP-Level on Real World Effectiveness of Upadacitinib as Monotherapy or in Combination With MTX in Adult Participants With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT04267536 Org: User:
Start: 02/06/20 End: 02/01/22 Due: 02/01/23

A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adult Participants With Hepatitis C Virus in French Addiction Centers

Phase: N/A Priority: Normal
NCT ID: NCT04366973 Org: User:
Start: 05/26/20 End: 12/31/23 Due: 12/31/24

A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

Phase: N/A Priority: Normal
NCT ID: NCT03607422 Org: User:
Start: 07/27/18 End: 11/04/25 Due: 11/04/26

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil

Phase: N/A Priority: Normal
NCT ID: NCT02442271 Org: User:
Start: 04/27/15 End: 09/26/16 Due: 09/26/17

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

Phase: N/A Priority: Normal
NCT ID: NCT05618028 Org: User:
Start: 04/04/23 End: 06/30/27 Due: 06/30/28

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection

Phase: N/A Priority: Normal
NCT ID: NCT01833533 Org: User:
Start: 03/31/13 End: 09/30/14 Due: 09/30/15

Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia

Phase: N/A Priority: Normal
NCT ID: NCT04403763 Org: User:
Start: 07/27/20 End: 12/05/22 Due: 12/05/23